Loading…
Perspective Therapeutics, Inc. is projected to rise to $5.31 by 2027, a +28% move from its current price of $4.16. CATX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.03 | $4.16 | $4.29 | +0.05% |
| May 30 | $3.99 | $4.16 | $4.35 | +0.10% |
| May 31 | $3.95 | $4.17 | $4.40 | +0.16% |
| Jun 1 | $3.92 | $4.17 | $4.44 | +0.21% |
| Jun 2 | $3.89 | $4.17 | $4.47 | +0.26% |
| Jun 3 | $3.87 | $4.17 | $4.50 | +0.31% |
| Jun 4 | $3.85 | $4.18 | $4.53 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.85 | $4.18 | $4.53 | +0.36% |
| Week 2 | $3.73 | $4.19 | $4.71 | +0.73% |
| Week 3 | $3.65 | $4.21 | $4.85 | +1.09% |
| Week 4 | $3.58 | $4.22 | $4.97 | +1.46% |
| Week 5 | $3.53 | $4.24 | $5.09 | +1.83% |
| Week 6 | $3.48 | $4.25 | $5.20 | +2.20% |
| Week 7 | $3.43 | $4.27 | $5.30 | +2.57% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Perspective Therapeutics, Inc. is a healthcare company focused on radiopharmaceutical development in the United States. It develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
The company’s pipeline includes VMT-a-NET in Phase 1/2a for unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy; VMT01 in Phase 1/2a for second-line or later treatment of MC1R-positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. Perspective Therapeutics also develops Pluvicto, a beta-emitting radioligand therapy to treat progressive PSMA-positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
CATX is a healthcare stock identified by its current price of $3.98 and a market cap of $453.9M, with a rank of 3111. The stock trades in a context where the thirty-day technical picture shows a range from $3.23 to $4.90, with a sentiment labeled as BULLISH. The current price sits near key moving averages, with the 50-day simple moving average at $4.21 and the 200-day simple moving average at $3.62.
A near-term support level is seen at $3.60 and a resistance level at $4.71. The 30-day range and these moving averages provide a framework for the evolving price trajectory. The longer-term forecast projects a rising price path with an average price of $3.98 in 2026, then higher in subsequent years, including an average of $7.26 in 2030 (with a max of $10.93 and an ROI of 82.4%), and continuing bullish momentum through 2050 (average $27.50, max $53.83, ROI 590.9%).
The forecast highlights a multi-year upside, tempered by the inherent uncertainties of market movements.
A major floor 44.0% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
The nearest ceiling, 13.2% above — a clean break opens room to run.
A major ceiling 35.8% above — clearing it would confirm fresh momentum.
Key CATX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CATX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.99 | Buy | $4.02 | Buy |
| MA 10 | $3.89 | Buy | $3.95 | Buy |
| MA 20 | $3.85 | Buy | $3.96 | Buy |
| MA 50 | $4.17 | Sell | $4.10 | Buy |
| MA 100 | $4.18 | Sell | $4.04 | Buy |
| MA 200 | $3.63 | Buy | $3.97 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.19 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 193.15 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 10.64 | Buy |
| Bollinger %B (20,2) | 1.04 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.47 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 64.93 | Neutral |
| Momentum (10) | 0.39 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 4.14 | Buy |
| ADX (14) | 14.22 | Neutral |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is labeled as BULLISH. The RSI(14) is 50, indicating a neutral momentum around the midline. The stock is interacting with the moving averages, with the SMA50 at $4.21 and the SMA200 at $3.62, suggesting a near-term balance between short-term momentum and longer-term trend.
A nearby support level is at $3.60 and a resistance level at $4.71, framing the potential move within the $3.60–$4.71 zone. Over the last 30 days, the price range has been $3.23 to $4.90, illustrating modest volatility within a constructive setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.33 | $4.16 | $5.88 | 0% | Neutral | |
| $4.15 | $5.31 | $7.22 | +28% | Bullish | |
| $5.23 | $6.90 | $9.76 | +66% | Bullish | |
| $5.35 | $7.24 | $10.57 | +74% | Bullish | |
| $5.69 | $7.89 | $11.82 | +90% | Bullish | |
| $5.74 | $8.13 | $12.47 | +95% | Bullish | |
| $5.31 | $7.66 | $12.00 | +84% | Bullish | |
| $6.18 | $9.09 | $14.51 | +119% | Bullish | |
| $7.00 | $10.49 | $17.04 | +152% | Bullish | |
| $7.56 | $11.52 | $19.01 | +177% | Bullish | |
| $8.60 | $14.19 | $25.04 | +241% | Bullish | |
| $16.80 | $31.88 | $61.99 | +666% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.33 | $4.16 | $4.88 | +0.00% |
| June 2026 | $3.59 | $4.23 | $5.11 | +1.72% |
| July 2026 | $3.67 | $4.36 | $5.35 | +3.06% |
| August 2026 | $3.59 | $4.30 | $5.34 | -1.38% |
| September 2026 | $3.62 | $4.36 | $5.46 | +1.40% |
| October 2026 | $3.81 | $4.62 | $5.84 | +6.04% |
| November 2026 | $3.85 | $4.69 | $5.97 | +1.46% |
| December 2026 | $3.75 | $4.59 | $5.88 | -2.18% |
Click any year to see its month-by-month CATX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Perspective Therapeutics, Inc.'s 2026 outlook centres on $4.16, within a $2.33 to $5.88 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CATX could reach as high as $7.22, with a base case around $5.31 and support toward $4.15 — roughly +28% from $4.16. Momentum favours further upside here.
Expect CATX to range from $5.23 to $9.76 through 2028. The $6.90 average target implies a +66% move from current prices. That is up +30% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CATX price prediction for 2029 points to an average of $7.24 (low $5.35, high $10.57) — a potential gain of +74% on today's $4.16. Momentum favours further upside here.
In 2030, CATX is projected to trade between $5.69 and $11.82, averaging $7.89 — a potential gain of +90% from today's $4.16. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Perspective Therapeutics, Inc.'s 2031 outlook centres on $8.13, within a $5.74 to $12.47 range. That is up +3% on the projected 2030 average. That marks a +95% change versus current levels. Momentum favours further upside here.
By 2032, CATX could reach as high as $12.00, with a base case around $7.66 and support toward $5.31 — roughly +84% from $4.16. Buyers look set to stay in control over this stretch.
Expect CATX to range from $6.18 to $14.51 through 2033. The $9.09 average target implies a +119% move from current prices. That is up +19% on the projected 2032 average. Momentum favours further upside here.
The CATX price prediction for 2034 points to an average of $10.49 (low $7.00, high $17.04) — a potential gain of +152% on today's $4.16. Buyers look set to stay in control over this stretch.
In 2035, CATX is projected to trade between $7.56 and $19.01, averaging $11.52 — a potential gain of +177% from today's $4.16. That is up +10% on the projected 2034 average. Momentum favours further upside here.
Perspective Therapeutics, Inc.'s 2040 outlook centres on $14.19, within a $8.60 to $25.04 range. That is up +23% on the projected 2035 average. That marks a +241% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CATX could reach as high as $61.99, with a base case around $31.88 and support toward $16.80 — roughly +666% from $4.16. Momentum favours further upside here.
Investing $1,000 in CATX today (≈ 240.384615 CATX) could be worth
$7,663.91
+$6,663.91 (+666%) by 2050 · US Dollar
Based on the average projected CATX price of $31.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CATXwould be worth at today's price.
$1,000 invested in CATX on May 27, 2025 (≈ 416.66665 CATX) would be worth
$1,733.33
+$733.33 (+73.3%) today · 1.73× · US Dollar
Based on a CATX entry price of $2.4 vs. today's $4.16.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.77 | $1,103.45 | +10.3% |
| 1 month ago | $4.27 | $974.24 | -2.6% |
| 3 months ago | $5.06 | $822.13 | -17.8% |
| 6 months ago | $2.35 | $1,770.21 | +77.0% |
| 1 year ago | $2.4 | $1,733.33 | +73.3% |
| All time (5.0y) ago | $8.3 | $501.2 | -49.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CATX forecast.
Our base-case forecast reaches $8.30 around 2033.
Implied market cap at $8.30: $946.58M
The multi-year forecast presents a bullish trajectory with rising averages and substantial upside potential. In 2026 the average price is $3.98, with subsequent years showing growth toward higher levels: 2027 average $4.97, 2028 $6.39, 2029 $6.70, and 2030 $7.26. The forecast for 2030 projects a max of $10.93 and an ROI of 82.4, signaling meaningful upside from current levels.
Beyond 2030, the path remains bullish, with 2031 average $7.37, 2032 $6.92, 2033 $8.19, 2034 $9.26, and 2035 $10.18, each accompanied by rising max values and favorable ROIs. By 2040 the average price increases to $12.29 and the max to $21.80, with an ROI of 208.7. The 2050 forecast shows an average of $27.50 and a max of $53.83, supported by a projected ROI of 590.9 and a bullish sentiment.
These projections are paired with higher volatility, as indicated by an annualized volatility of 60%. While the outlook is positive, investors should recognize the inherent uncertainty and the possibility of downside risk.
Tap a question to reveal the answer.
In 2030 the forecast shows a min of $5.22, an average of $7.26, and a max of $10.93, with an ROI of 82.4% and a bullish sentiment.
The forecast indicates bullish sentiment from 2027 onward, with rising averages: 2027 average $4.97, 2028 $6.39, 2029 $6.70, 2030 $7.26, and 2031 $7.37, plus increasing ROIs culminating in 590.9% by 2050. These are estimates, not guarantees, and reflect higher volatility (annualized volatility 60%). The current price is $3.98 with a market cap of $453.9M.
Yes. The 2050 maximum forecast is $53.83, which implies a potential reach above $20 according to the projection.
The current price is $3.98 and the market cap is $453.9M.
The 30-day range is $3.23 to $4.90. RSI(14) is 50. The 50-day SMA is $4.21 and the 200-day SMA is $3.62. Support is at $3.60 and resistance at $4.71.
Perspective Therapeutics, Inc. Community Discussion
0Share your Perspective Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.